Cover Image

177Lu-FA-DOTA-PEG-PLGA Nanoparticles Show Antitumor Efficiency in Targeting Ovarian Cancer

Background: The development of novel therapies holds significance in improving the prognosis of ovarian cancer (OC). This study aimed to prepare 177Lu-FA-DOTA-PEG-PLGA nanoparticles and evaluate their antitumor efficacy in OC. Methods: To obtain nanoparticles with both targeting and degradable prope...

Full description

Saved in:

Bibliographic Details
Main Authors:	Ziming Guo (Author), Yi Du (Author), Jun Zhao (Author), Sha Sha (Author), Jian Wang (Author)
Format:	Book
Published:	IMR Press, 2024-05-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Chilean experience using "Theranostics" for treating metastatic neuroendocrine tumors with [177Lu]Lu DOTA-TATE
by: Horacio Amaral, et al.
Published: (2020)

Distinct In Vitro Binding Profile of the Somatostatin Receptor Subtype 2 Antagonist [<sup>177</sup>Lu]Lu-OPS201 Compared to the Agonist [<sup>177</sup>Lu]Lu-DOTA-TATE
by: Rosalba Mansi, et al.
Published: (2021)

First-In-Human Results on the Biodistribution, Pharmacokinetics, and Dosimetry of [<sup>177</sup>Lu]Lu-DOTA.SA.FAPi and [<sup>177</sup>Lu]Lu-DOTAGA.(SA.FAPi)<sub>2</sub>
by: Sanjana Ballal, et al.
Published: (2021)

Radioligand Therapy with [<sup>177</sup>Lu]Lu-DOTA-TATE or [<sup>177</sup>Lu]Lu-DOTA-TATE and [<sup>90</sup>Y]Y-DOTA-TATE in Patients with Neuroendocrine Neoplasms of Unknown Locations, or Locations Other Than the Midgut and Pancreas as Primaries in a G1, G2 and G3 Grade
by: Adam Daniel Durma, et al.
Published: (2023)

Optimization of 177Lu-labelling of DOTA-TOC, PSMA-I&T and FAPI-46 for clinical application
by: Aylin Cankaya, et al.
Published: (2023)

First preclinical evaluation of [225Ac]Ac-DOTA-JR11 and comparison with [177Lu]Lu-DOTA-JR11, alpha versus beta radionuclide therapy of NETs
by: Maryana Handula, et al.
Published: (2023)

In vitro characterisation of [177Lu]Lu-DOTA-C595 as a novel radioimmunotherapy for MUC1-CE positive pancreatic cancer
by: Ashleigh Hull, et al.
Published: (2023)

Comparison of the Anti-Tumour Activity of the Somatostatin Receptor (SST) Antagonist [<sup>177</sup>Lu]Lu-Satoreotide Tetraxetan and the Agonist [<sup>177</sup>Lu]Lu-DOTA-TATE in Mice Bearing AR42J SST<sub>2</sub>-Positive Tumours
by: Pascale Plas, et al.
Published: (2022)

The development of 177Lu-DOTA-CC-PSMA following a unified "Click Chemistry" protocol of synthesizing metal nuclide-conjugated radiopharmaceuticals
by: Xiaobei Zheng, et al.
Published: (2024)

Comparative Preclinical Evaluation of HER2-Targeting ABD-Fused Affibody<sup>®</sup> Molecules <sup>177</sup>Lu-ABY-271 and <sup>177</sup>Lu-ABY-027: Impact of DOTA Position on ABD Domain
by: Yongsheng Liu, et al.
Published: (2021)

Evaluation of the 177mLu-concentration in in-house produced 177Lu-radiopharmaceuticals and commercially available Lutathera®
by: Matthias Balzer, et al.
Published: (2023)

Dose predictions for [177Lu]Lu-DOTA-panitumumab F(ab')2 in NRG mice with HNSCC patient-derived tumour xenografts based on [64Cu]Cu-DOTA-panitumumab F(ab')2 - implications for a PET theranostic strategy
by: Anthony Ku, et al.
Published: (2021)

Improved quality control of [177Lu]Lu-PSMA I&T
by: Martin Kraihammer, et al.
Published: (2023)

Preclinical comparison of [177Lu]Lu-rhPSMA-10.1 and [177Lu]Lu-rhPSMA-10.2 for endoradiotherapy of prostate cancer: biodistribution and dosimetry studies
by: Alexander Wurzer, et al.
Published: (2024)

Radionuclide generator-based production of therapeutic 177Lu from its long-lived isomer 177mLu
by: Rupali Bhardwaj, et al.
Published: (2019)

Combination of [<sup>177</sup>Lu]Lu-DOTA-TATE Targeted Radionuclide Therapy and Photothermal Therapy as a Promising Approach for Cancer Treatment: In Vivo Studies in a Human Xenograft Mouse Model
by: Marina Simón, et al.
Published: (2022)

Drug-loaded PEG-PLGA nanoparticles for cancer treatment
by: Dan Zhang, et al.
Published: (2022)

68Ga, 44Sc and 177Lu-labeled AAZTA5-PSMA-617: synthesis, radiolabeling, stability and cell binding compared to DOTA-PSMA-617 analogues
by: Jean-Philippe Sinnes, et al.
Published: (2020)

Impact of DOTA Conjugation on Pharmacokinetics and Immunoreactivity of [<sup>177</sup>Lu]Lu-1C1m-Fc, an Anti TEM-1 Fusion Protein Antibody in a TEM-1 Positive Tumor Mouse Model
by: Judith Anna Delage, et al.
Published: (2021)

PEG-lipid-PLGA hybrid nanoparticles loaded with berberine-phospholipid complex to facilitate the oral delivery efficiency
by: Fei Yu, et al.
Published: (2017)

177Lu-PSMA-617 for metastatic prostate cancer in India
by: Aruni Ghose, et al.
Published: (2024)

Evaluation of β-Sitosterol Loaded PLGA and PEG-PLA Nanoparticles for Effective Treatment of Breast Cancer: Preparation, Physicochemical Characterization, and Antitumor Activity
by: Moses Andima, et al.
Published: (2018)

Quality control of [177Lu]Lu-PSMA preparations using HPLC: effect of sample composition and ligand on recovery
by: Else A. Aalbersberg, et al.
Published: (2022)

Characterization of Non-Specific Uptake and Retention Mechanisms of [<sup>177</sup>Lu]Lu-PSMA-617 in the Salivary Glands
by: Nathalie Heynickx, et al.
Published: (2023)

In Vitro Biological Evaluation of Aprepitant Based <sup>177</sup>Lu-Radioconjugates
by: Paweł K. Halik, et al.
Published: (2022)

[<sup>177</sup>Lu]Lu-PSMA-617 Salivary Gland Uptake Characterized by Quantitative <i>In Vitro</i> Autoradiography
by: Roswitha Tönnesmann, et al.
Published: (2019)

Assessment of the Effect of PLGA Co-polymers and PEG on the Formation and Characteristics of PLGA-PEG-PLGA Co-block Polymer Using Statistical Approach
by: Teuku Nanda Saifullah Sulaiman, et al.
Published: (2019)

Enhanced tumor suppression in colorectal cancer via berberine-loaded PEG-PLGA nanoparticles
by: Fei Shen, et al.
Published: (2024)

PLGA-PEG Nanoparticles Loaded with Cdc42 Inhibitor for Colorectal Cancer Targeted Therapy
by: Sanazar Kadyr, et al.
Published: (2024)

Effect of Size and Concentration of PLGA-PEG Nanoparticles on Activation and Aggregation of Washed Human Platelets
by: Rana Bakhaidar, et al.
Published: (2019)

Preparation, Characterization, and Biological Evaluation of a Hydrophilic Peptide Loaded on PEG-PLGA Nanoparticles
by: Lisa Marinelli, et al.
Published: (2022)

Improving Overall Survival and Quality of Life in Patients with Prostate Cancer and Neuroendocrine Tumors Using <sup>177</sup>Lu-iPSMA and <sup>177</sup>Lu-DOTATOC: Experience after 905 Treatment Doses
by: Myrna Luna-Gutiérrez, et al.
Published: (2023)

Radiolabeling and quality control of therapeutic radiopharmaceuticals: optimization, clinical implementation and comparison of radio-TLC/HPLC analysis, demonstrated by [177Lu]Lu-PSMA
by: Eline L. Hooijman, et al.
Published: (2022)

[<sup>177</sup>Lu]Lu-PSMA-617 (Pluvicto<sup>TM</sup>): The First FDA-Approved Radiotherapeutical for Treatment of Prostate Cancer
by: Ute Hennrich, et al.
Published: (2022)

Fully-automated synthesis of 177Lu labelled FAPI derivatives on the module modular lab-Eazy
by: Kurtulus Eryilmaz, et al.
Published: (2021)

Development and Validation of Analytical Methods for Radiochemical Purity of <sup>177</sup>Lu-PSMA-1
by: Pauline Orhon, et al.
Published: (2022)

Thermosensitive PLGA-PEG-PLGA Hydrogel as Depot Matrix for Allergen-Specific Immunotherapy
by: Sonja Heine, et al.
Published: (2022)

RadioLigand Therapy with [<sup>177</sup>Lu]Lu-PSMA-617 for Salivary Gland Cancers: Literature Review and First Compassionate Use in France
by: Marie Terroir, et al.
Published: (2023)

PLGA-PEG-ANG-2 Nanoparticles for Blood-Brain Barrier Crossing: Proof-of-Concept Study
by: Gina P. Hoyos-Ceballos, et al.
Published: (2020)

PEG 400:Trehalose Coating Enhances Curcumin-Loaded PLGA Nanoparticle Internalization in Neuronal Cells
by: Isaac H. Caballero-Florán, et al.
Published: (2023)